| Quality of life after immune suppressive therapy in aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion |
|
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
| Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes |
|
Annals of internal medicine |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
|
Annals of Oncology: Official Journal of the European Society for Medical Oncology |
Myelodysplastic Syndromes (MDS) |
| A Journey from Blood Cells to Genes and Back |
|
Annual Review of Genomics and Human Genetics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy |
|
Annual Review of Pathology: Mechanisms of Disease |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms |
|
Archives of Pathology & Laboratory Medicine |
Myelodysplastic Syndromes (MDS) |
| MDS/MPN-RS-T Justified Inclusion as a Unique Disease Entity? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
